



中國抗體製藥有限公司
SinoMab BioScience Limited

**SinoMab Acquired a Land Parcel of 43,333 sq.m. in Suzhou Industrial Park
For the Construction of its China Campus**
Further Improved Production Capacity and Commercialization Layout

[24 June 2020, Hong Kong] **SinoMab BioScience Limited** (“SinoMab” or the “Company”, stock code: **3681.HK**), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that SinoLink Pharma (Suzhou) Limited (“SinoLink Pharma”), a wholly-owned subsidiary of the Company, has acquired a land parcel of 43,333 sq.m. in Suzhou Industrial Park. The land parcel will be used for the construction of an industrialization base with an estimated production capacity of over 30,000L.

SinoMab comprises a full-spectrum platform which consists of target identification, drug candidate development, pre-clinical research, clinical trials, clinical production, quality control, quality assurance, regulatory approval and commercial-scale production. The Company has a GMP-compliant manufacturing plant in Haikou with a production capacity of 1,200L. As part of the future development plan, the Company is building a new production base with 6,000L production capacity in Suzhou BioBAY, which is expected to commence operation in the second half of 2021.

Dr. Shui On Leung, the Executive Director, Chairman and Chief Executive Officer of SinoMab, said: “The land parcel of 43,333 sq.m. acquired from the Suzhou government and Suzhou BioBAY will be utilized to build our campus in China, which will comprise the Company’s PRC headquarter, R&D center and a second production base, and will possess a full-fledged ability to conduct vertical integration from R&D to production and marketing. The construction of our Suzhou campus will build a foundation for our drug candidates’ further R&D and commercialization, and Suzhou will become SinoMab’s headquarter of R&D, production and marketing. With a proactive layout for global development, we now have a physical presence in Hong Kong, Haikou, Suzhou and Australia, dedicating to forging ourselves to be a global biopharmaceutical company with various products and sustainable development to fulfill the rising demand for premium healthcare.”

Mr. Jing Qiang, the Executive Director and President of SinoMab, said in a media interview that as SinoMab’s commercial-scale production center, SinoLink Pharma will mainly focus on the clinical

trials of SM03 and SN1011 and the Investigational New Drug (“IND”) filing of SM17 in the future. SM03 is a potential global first-in-target anti-CD22 mAb for the treatment of rheumatoid arthritis (RA) and currently in its Phase III clinical trials. The Company recently disclosed that as of 19 June 2020, 290 eligible patients were randomized into the clinical trial and phase III clinical trial interim analysis was completed. The interim analysis showed that among such 290 patients, 84% of the patients have completed the 24-week primary endpoint visit, 46% have completed the 52-week extended period study and less than 12% dropped out before the 52-week endpoint of the study, reflecting a satisfactory adherence to the study treatment in the study. A satisfactory safety and tolerability profile, which is generally in line with what had been observed in phase II study, has been shown in the patients recruited. SN1011 is now in Phase I clinical trial in Australia and the single arising dose study has completed, showing satisfactory safety. The submission of IND in China is in preparation as well. Furthermore, SM17, SinoMab’s first-in-class mAb against the receptor IL17BR cooperated with the Cambridge University is expected to file IND in America or the European region.

Mr. Jing Qiang said, in the mAb field, the layout of target discovery will become a key element affecting competitiveness in the future. Since establishment, SinoMab has always focused on the discovery and development of novel drug targets. As first-in-target and first-in-class drug candidates worldwide, SM03 and SM17 has obtained a differentiation advantage from the beginning. Meanwhile, most marketed biological drugs for RA are TNF- α inhibitors, and SM03 provides a potential treatment for the patients who has experienced TNF- α resistance or failure. It creates a differentiated approach to the market for SM03. China’s immunological disease market has great potential in the future. SinoMab will continue to improve its innovative drug target R&D capability and build R&D, clinical and marketing teams focusing on immunological disease treatments. While push forward R&D and marketing of drug candidates and initiate production base construction, the Company will enhance its innovative products layout to create a solid foundation for long-term development.



SinoLink Pharma presented the handover ceremony of Suzhou Industrial Park land parcel on 24 June 2020

About SinoMab BioScience Limited

SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: **3681.HK**) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.

This press release is issued by Porda Havas International Finance Communications Group for and on behalf of **SinoMab BioScience Limited**. For further information, please contact:

Porda Havas International Finance Communications Group

Mr. Bunny Lee

+852 3150 6707

bunny.lee@pordahavas.com

Ms. Angela Shi

+852 3150 6778

angela.shi@pordahavas.com